SinoMab Dosed First Healthy Subject in PI Trial of SM17 in the U.S.
15 Jun 2022 //
ASIAONE
Everest inks $561M biobucks deal for renal disease treatment
18 Sep 2021 //
FIERCEBIOTECH
Everest Medicines, Sinovent & SinoMab sign deal for BTKi in Renal Diseases
16 Sep 2021 //
PRNEWSWIRE